Macroaxis Story

Macroaxis News
  
By Achuva Shats

March 15, 2019

This post breaks downs 8 Medical Equipment isntruments to have in your portfolio in April 2019. I will cover the following entities: OrthoPediatrics Corp, Hologic, Glaukos Corporation, Medtronic plc, Hill Rom Holdings, The Cooper Companies, Boston Scientific Corporation, and Becton Dickinson and Company
The Top 8 Medical Equipment stocks to own in April 2019

This list of potential positions covers USA Equities from Medical Equipment industry as classified by Fama & French. Fama and French focuses on testing asset pricing under different economic assumptions in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.


OrthoPediatrics Corp (KIDS)

The company has Profit Margin (PM) of (16.71) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (13.1) % which suggests for every $100 dollars of sales it generated a net operating loss of -0.13. The firm currently falls under 'Small-Cap' category with current market capitalization of 530.38M. OrthoPediatrics Corp holds recent Real Value of $40.98 per share. The prevailing price of the company is $34.71. At this time the company appears to be undervalued. This module determines value of OrthoPediatrics Corp from analyzing the company fundamentals such as Operating Margin of (13.10)%, Shares Outstanding of 14.68M and Return On Equity of (16.10)% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we support investing in undervalued entities and to dispose of overvalued entities since at some point stocks prices and their ongoing real values will merge together.

Hologic (HOLX)

The company has return on total asset (ROA) of 5.04 % which means that it generated profit of $5.04 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of (0.46) % meaning that it created substantial loss on money invested by shareholders. This firm currently falls under 'Large-Cap' category with current market capitalization of 12.62B.
Total Debt
Hologic competes with Electrocore, Ekso Bionics, Endologix, Baxter International, Becton Dickinson, Cantel Medical, Cooper Companies, Daxor, and Haemonetics. Hologic, Inc., a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company was founded in 1985 and is headquartered in Marlborough, Massachusetts. Hologic operates under Medical Instruments Supplies classification in USA and is traded on BATS Exchange. It employs 6252 people.

Glaukos Corporation (GKOS)

The company has Profit Margin (PM) of (5.93) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (5.75) % which suggests for every $100 dollars of sales it generated a net operating loss of -0.06. The firm currently falls under 'Mid-Cap' category with current market capitalization of 2.79B. Glaukos retains regular Real Value of $76.2583 per share. The prevalent price of the corporation is $75.83. At this time the corporation appears to be fairly valued. This module calculates value of Glaukos from evaluating the corporation fundamentals such as Return On Equity of (7.05)% and Return On Asset of (3.59)% as well as inspecting its technical indicators and Probability Of Bankruptcy. In general, we encourage to acquire undervalued assets and to sell overvalued assets since at some point stocks prices and their ongoing real values will come together. Glaukos competes with Electrocore, Ekso Bionics, Endologix, Baxter International, Becton Dickinson, Cantel Medical, Cooper Companies, Daxor, and Haemonetics. Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California. Glaukos operates under Medical Instruments Supplies classification in USA and is traded on BATS Exchange. It employs 437 people.

Medtronic plc (MDT)

The company has Net Profit Margin of 15.15 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 30.22 % which entails that for every 100 dollars of revenue it generated 0.3 of operating income. The entity currently falls under 'Mega-Cap' category with total capitalization of 135.35B.
Total Debt

Hill Rom Holdings (HRC)

The company has Net Profit Margin of 7.93 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 19.76 % which entails that for every 100 dollars of revenue it generated 0.2 of operating income. The entity currently falls under 'Mid-Cap' category with total capitalization of 7.12B. Hill Rom Holdings retains regular Real Value of $110.1 per share. The prevalent price of the corporation is $104.75. At this time the corporation appears to be undervalued. This module calculates value of Hill Rom Holdings from evaluating the corporation fundamentals such as Current Valuation of 8.9B, Return On Equity of 14.62% and Return On Asset of 5.50% as well as inspecting its technical indicators and Probability Of Bankruptcy. In general, we encourage to acquire undervalued assets and to sell overvalued assets since at some point stocks prices and their ongoing real values will come together.

The Cooper Companies (COO)

The company has Net Profit Margin of 16.46 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 30.4 % which entails that for every 100 dollars of revenue it generated 0.3 of operating income. This firm currently falls under 'Large-Cap' category with total capitalization of 16.4B.
Total Debt
Cooper Companies competes with Electrocore, Ekso Bionics, Endologix, Baxter International, Becton Dickinson, Cantel Medical, Daxor, and Haemonetics. The Cooper Companies, Inc. operates as a medical device company worldwide. The Cooper Companies, Inc. was founded in 1980 and is headquartered in Pleasanton, California. Cooper Companies operates under Medical Instruments Supplies classification in USA and is traded on BATS Exchange. It employs 12000 people.

Boston Scientific Corporation (BSX)

The company has Net Profit Margin of 18.08 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 26.66 % which entails that for every 100 dollars of revenue it generated 0.27 of operating income. The entity currently falls under 'Large-Cap' category with total capitalization of 58.74B. Boston Scientific shows prevailing Real Value of $45.9514 per share. The current price of the firm is $42.5. At this time the firm appears to be undervalued. This module approximates value of Boston Scientific from analyzing the firm fundamentals such as Profit Margin of 18.08%, Current Valuation of 67.57B and Return On Equity of 22.10% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend. Boston Scientific shows prevailing Real Value of $45.9514 per share. The current price of the firm is $42.5. At this time the firm appears to be undervalued. This module approximates value of Boston Scientific from analyzing the firm fundamentals such as Profit Margin of 18.08%, Current Valuation of 67.57B and Return On Equity of 22.10% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend.

Becton Dickinson and Company (BDX)

The company has Net Profit Margin of 6.33 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 29.47 % which entails that for every 100 dollars of revenue it generated 0.29 of operating income. The entity currently falls under 'Large-Cap' category with total capitalization of 67.93B.
Total Debt
Becton Dickinson competes with Electrocore, Ekso Bionics, Endologix, Baxter International, Cantel Medical, Cooper Companies, Daxor, and Haemonetics. Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey. Becton Dickinson operates under Medical Instruments Supplies classification in USA and is traded on BATS Exchange. It employs 76032 people.

Current 8 Medical Equipment Recommendations

Competition Technical Indicators

Mean
Deviation
Jensen
Alpha
Sortino
Ratio
Treynor
Ratio
Semi
Deviation
Information
Ratio
Expected
Shortfall
Potential
Upside
Value
At Risk
Maximum
Drawdown
 4.21  0.24  0.02  0.54  4.81  0.0231 (8.74)  8.70 (10.71)  46.67 
 2.94 (0.54)  0.00  0.36  0.00 (0.18)  0.00  4.14 (7.09)  26.34 
 1.77 (0.11)  0.00 (0.05)  0.00 (0.06)  0.00  3.76 (4.02)  14.43 
 0.65  0.19  0.11  1.25  0.46  0.10 (0.75)  1.30 (1.23)  4.40 
 0.75  0.14  0.05  0.65  0.69  0.05 (0.82)  1.37 (1.28)  4.17 
 1.26  0.28  0.12  0.67  1.36  0.13 (1.37)  2.87 (2.30)  7.70 
 0.84  0.26  0.17  1.27  0.64  0.15 (0.99)  2.46 (1.23)  6.08 
 2.24  0.12 (0.02) (0.09)  2.73 (0.02) (2.66)  4.50 (4.40)  20.92 
 0.93  0.37  0.25  0.82  0.79  0.23 (1.16)  2.67 (1.33)  5.00 
 0.76  0.16  0.07  0.90  0.70  0.07 (0.83)  1.52 (1.27)  5.60 

About Contributor

Achuva Shats
   Achuva Shats is a Member of Macroaxs Editorial Board. Achuva writes about retail product and service companies from the prospective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce View Profile
This story should be regarded as informational only and should not be considered as solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Macroaxis. Please refer to our Terms of Use for any information regarding our disclosure principles.

Did you try this?

Run CEO Directory Now

   

CEO Directory

Screen CEOs from public companies around the world
All  Next Launch Module
See also Stocks Correlation. Please also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Search macroaxis.com